



Tom has over 25 years of experience studying genetic causes of human diseases such as cancer, deafness, myotonic dystrophy, and other inherited diseases. During his postdoctoral fellowship at Johns Hopkins Medical Institute, Tom's discoveries contributed to the first exome studies of cancer. He began his industry career at Eli Lilly in 2006 as an oncology drug hunter and biomarker developer. In 2010, Tom created and led the Next Generation Sequencing platform at Eli Lilly which identified preclinical and clinical models for personalized medicine in oncology, diabetes, neuroscience, and cardiovascular disease. In 2014, Tom became the genomics leader at Beckman Coulter developing solutions for NGS sample preparation. Tom has studied human molecular genetics throughout his career, earning a BS in Zoology-Genetics from Michigan State University in 1993, a MS in Human and Molecular Genetics from Baylor College of Medicine in 1995, and a PhD in Genetics from Michigan State University in 2000.

# Tom Barber

Chief Scientific Officer  
LifeOmic

---